Agenus Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AGEN Nasdaq 2834 www.agenusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agenus Inc.

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers - Dec 18th, 2024 12:30 pm
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B - Dec 6th, 2024 11:07 am
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Dec 5th, 2024 12:30 pm
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development - Nov 27th, 2024 3:20 pm
Agenus Secures $22 Million Mortgage, Plans Operational Realignment; Shares Jump - Nov 27th, 2024 3:12 pm
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Nov 27th, 2024 1:15 pm
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nov 19th, 2024 2:35 pm
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nov 18th, 2024 2:35 pm
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround - Nov 15th, 2024 2:35 pm
Q3 2024 Agenus Inc Earnings Call - Nov 13th, 2024 7:18 am
Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... - Nov 13th, 2024 7:08 am
Agenus (AGEN) Q3 2024 Earnings Call Transcript - Nov 12th, 2024 5:15 pm
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2024 1:20 pm
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development - Nov 12th, 2024 12:00 pm
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 - Nov 7th, 2024 3:00 pm
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Nov 5th, 2024 12:30 pm
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 - Sep 13th, 2024 2:00 pm
Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results - Sep 9th, 2024 7:02 pm
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 - Sep 9th, 2024 11:30 am
Agenus to Participate in September Investor Conferences - Sep 3rd, 2024 11:30 am